Optimization of the Interaction between Diclofenac and Ibuprofen with Benzalkonium Chloride to Prepare Ocular Nanosuspension

Author(s): Deepika Tak, Rimpy, Tarun Kumar, Munish Ahuja*

Journal Name: Recent Patents on Drug Delivery & Formulation

Volume 13 , Issue 4 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Non-steroidal anti-inflammatory drugs are most commonly used in the management of ocular inflammations. These drugs have poorly aqueous solubility and weakly acidic nature. They interact with cationic quaternary ammonium compound benzalkonium chloride, used as a preservative in ophthalmic formulations, to form insoluble complexes. To overcome this incompatibility solubilizers like polysorbate 80, lysine salts, tocopheryl polyethylene glycol succinate etc. are used which are quite irritating and affect the corneal integrity.

Objective: The objective of the present study is to formulate nonirritating, compatible, microbiologically stable ophthalmic formulation with good corneal permeation characteristics. The interaction between diclofenac sodium or ibuprofen with benzalkonium chloride was optimized using a central composite experimental design to prepare nanosuspensions by nanoprecipitation.

Methods: The optimized batches of nanosuspensions were evaluated for ex vivo corneal permeation study, preservative challenge test and physical stability. The optimal concentrations of benzalkonium chloride for diclofenac sodium (0.1%, w/v) and ibuprofen (0.1% w/v) nanosuspensions were determined to be 0.002%(w/v), which had a respective average particle size of 440 nm and 331 nm, respectively. The nanosuspensions of diclofenac sodium and ibuprofen provided 1.6 and 2.1- fold higher ex vivo corneal permeation than their respective conventional aqueous solution dosage forms. Further, the concentration of benzalkonium chloride used in the formulations showed adequate preservative efficacy.

Results: The optimized nanosuspension formulations of diclofenac and ibuprofen were found to be physically stable and microbiologically safe with greater corneal penetration than the conventional solution dosage forms.

Keywords: Benzalkonium chloride, diclofenac, ibuprofen, nanosuspension, ophthalmic, corneal permeation.

[1]
Patel, A.; Cholkar, K.; Agrahari, V.; Mitra, A.K. Ocular drug delivery systems: An overview. World J. Pharmacol., 2013, 2(2), 47-64.
[http://dx.doi.org/10.5497/wjp.v2.i2.47] [PMID: 25590022]
[2]
Coroi, M.C.; Bungau, S.; Tit, M. Preservatives from the eye drops and the ocular surface. Rom. J. Ophthalmol., 2015, 59(1), 2-5.
[PMID: 27373107]
[3]
Baudouin, C.; Labbé, A.; Liang, H.; Pauly, A.; Brignole-Baudouin, F. Preservatives in eyedrops: the good, the bad and the ugly. Prog. Retin. Eye Res., 2010, 29(4), 312-334.
[http://dx.doi.org/10.1016/j.preteyeres.2010.03.001] [PMID: 20302969]
[4]
Baudouin, C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol., 2008, 86(7), 716-726.
[http://dx.doi.org/10.1111/j.1755-3768.2008.01250.x] [PMID: 18537937]
[5]
Gaynes, B.I.; Onyekwuluje, A. Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension. Clin. Ophthalmol., 2008, 2(2), 355-368.
[http://dx.doi.org/10.2147/OPTH.S1067] [PMID: 19668727]
[6]
Schalnus, R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica, 2003, 217(2), 89-98.
[http://dx.doi.org/10.1159/000068563] [PMID: 12592044]
[7]
Ahuja, M.; Dhake, A.S.; Sharma, S.K.; Majumdar, D.K. Topical ocular delivery of NSAIDs. AAPS J., 2008, 10(2), 229-241.
[http://dx.doi.org/10.1208/s12248-008-9024-9] [PMID: 18437583]
[8]
Ahuja, M.; Dhake, A.S.; Sharma, S.K.; Majumdar, D.K. Diclofenac-loaded Eudragit S100 nanosuspension for ophthalmic delivery. J. Microencapsul., 2011, 28(1), 37-45.
[http://dx.doi.org/10.3109/02652048.2010.523794] [PMID: 21171815]
[9]
Epstein, S.P.; Chen, D.; Asbell, P.A. Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells. J. Ocul. Pharmacol. Ther., 2009, 25(5), 415-424.
[http://dx.doi.org/10.1089/jop.2008.0140] [PMID: 19857103]
[10]
Ahuja, M.; Dhake, A.S.; Majumdar, D.K. Effect of formulation factors on in-vitro permeation of diclofenac from experimental and marketed aqueous eye drops through excised goat cornea. Yakugaku Zasshi, 2006, 126(12), 1369-1375.
[http://dx.doi.org/10.1248/yakushi.126.1369] [PMID: 17139162]
[11]
Reer, O.; Bock, T.K.; Müller, B.W. In vitro corneal permeability of diclofenac sodium in formulations containing cyclodextrins compared to the commercial product voltaren ophtha. J. Pharm. Sci., 1994, 83(9), 1345-1349.
[http://dx.doi.org/10.1002/jps.2600830928] [PMID: 7830253]
[12]
Quint Eana-Hau, D.J.; Cruz-Olmos, E.; Lopez-Sanchez, I.M. Characterization of the novel ophthalmic drug carrier Sophisen in two of its derivatives: 3A OftenoTM and Modusik-A oftenoTM. Drug Dev. Ind. Pharm., 2003, 31, 263-269.
[http://dx.doi.org/10.1081/DDC-52058]
[13]
Hargrave, S.L.; Jung, J.C.; Fini, M.E.; Gelender, H.; Cather, C.; Guidera, A.; Udell, I.; Fisher, S.; Jester, J.V.; Bowman, R.W.; McCulley, J.P.; Cavanagh, H.D. Possible role of the vitamin E solubilizer in topical diclofenac on matrix metalloproteinase expression in corneal melting: an analysis of postoperative keratolysis. Ophthalmology, 2002, 109(2), 343-350.
[http://dx.doi.org/10.1016/S0161-6420(01)00930-7] [PMID: 11825822]
[14]
Pignatello, R.; Bucolo, C.; Spedalieri, G.; Maltese, A.; Puglisi, G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 2002, 23(15), 3247-3255.
[http://dx.doi.org/10.1016/S0142-9612(02)00080-7] [PMID: 12102196]
[15]
Gupta, A.K.; Madan, S.; Majumdar, D.K.; Maitra, A. Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies. Int. J. Pharm., 2000, 209(1-2), 1-14.
[http://dx.doi.org/10.1016/S0378-5173(00)00508-1] [PMID: 11084241]
[16]
Bucolo, C.; Maltese, A.; Puglisi, G.; Pignatello, R. Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspension. Ophthalmic Res., 2002, 34(5), 319-323.
[http://dx.doi.org/10.1159/000065608] [PMID: 12381895]
[17]
Thakkar, H.P.; Patel, B.V.; Thakkar, S.P. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement. J. Pharm. Bioallied Sci., 2011, 3(3), 426-434.
[http://dx.doi.org/10.4103/0975-7406.84459] [PMID: 21966165]
[18]
Minkal, A.M.; Bhatt, D.C. Carboxymethyl gum katira: Synthesis, characterization, and evaluation for nanoparticulate drug delivery. RSC Advances, 2015, 5, 82363-82373.
[http://dx.doi.org/10.1039/C5RA11702J]
[19]
Lucero, JC Enhancement of benzalkonium chlorde preservative activity in formulations containing an incompatible drug. US5,504,113 (1996).
[20]
Li, Q.; Chen, F.; Liu, Y.; Yu, S.; Gai, X.; Ye, M.; Yang, X.; Pan, W. A novel albumin wrapped nanosuspension of meloxicam to improve inflammation-targeting effects. Int. J. Nanomedicine, 2018, 13, 4711-4725.
[http://dx.doi.org/10.2147/IJN.S160714] [PMID: 30154656]
[21]
Digne, M.; Revel, R.; Boualleg, M. Innovative characterizations and morphology control of γ–AlOOH boehmite nanoparticles: Towards advanced tuning of γ–Al2O3 catalyst properties. Pharmaceutics, 2019, 11, 1-29.
[22]
Peneva, P.T. Non-steroidal anti-inflammatory drugs for topical ophthalmic administration - Contemporary trends. Int. J. Pharm. Pharm. Sci., 2015, 7, 13-19.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 4
Year: 2019
Page: [301 - 309]
Pages: 9
DOI: 10.2174/1872211314666191218105826
Price: $58

Article Metrics

PDF: 19
HTML: 2
EPUB: 1
PRC: 1